University of Rouen | Date: 2017-01-04
The invention relates to a double-porosity three-dimensional material comprising a support consisting of a polymer having a surface which comprises positive charges and is functionalised by bioactive molecules which comprise negative charges and are used to increase the proliferation of eukaryotic cells. It also relates to the production method thereof, and to the uses of same for fixing and stimulating the proliferation of eukaryotic cells.
University of Rouen and Center Henri Becquerel | Date: 2017-01-18
The present invention relates to a method for classifying a diffuse large B-cell lymphoma (DLBCL) of a subject into a GCB-DLBCL or into a ABC-DLBCL comprising the step of determining the expression level of 10 genes in a tumor tissue sample obtained from the subject by performing a Reverse Transcriptase Multiplex Ligation dependent Probe Amplification (RT-MLPA) assay wherein the 10 genes are NEK6, IRF4, IGHM, LMO2, FOXP1, TNFRSF9, BCL6, TNFRSF13B, CCND2 and MYBL1.
University of Paris Descartes, Assistance Publique Hopitaux De Paris, Chu De Rouen, French Institute of Health, Medical Research, University of Rouen and University Paris Diderot | Date: 2015-05-27
The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a ndsequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, a ndsequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a ndsequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, a nd (ii) at least 2 labelled probes respectively comprising or consisting of:sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, andsequence SEQ ID NO: 6, a sequence complementary to SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complementary thereof, and b) determining therefrom the presence or absence and/or the quantity of HIV-2 nucleic acids in the biological sample.
University of Rouen and Chu De Rouen | Date: 2017-04-05
The present invention relates to a method for detecting or quantifying Human Immunodeficiency Virus-2 (HIV-2) nucleic acids in a biological sample, comprising: a) performing a real-time polymerase chain reaction (PCR) or a real-time reverse transcriptase polymerase chain reaction (RT-PCR) on nucleic acids of the biological sample with: (i) at least 4 primers respectively comprising or consisting of: - sequence SEQ ID NO: 1 or a sequence having at least 90% identity to SEQ ID NO: 1, a nd - sequence SEQ ID NO: 2 or a sequence having at least 90% identity to SEQ ID NO: 2, a nd - sequence SEQ ID NO: 4 or a sequence having at least 90% identity to SEQ ID NO: 4, a nd - sequence SEQ ID NO: 5 or a sequence having at least 90% identity to SEQ ID NO: 5, a nd (ii) at least 2 labelled probes respectively comprising or consisting of: - sequence SEQ ID NO: 3, a sequence complementary to SEQ ID NO: 3, or a sequence having at least 90% identity to SEQ ID NO: 3 or the complementary thereof, and - sequence SEQ ID NO: 6, a sequence complementary to SEQ ID NO: 6, or a sequence having at least 90% identity to SEQ ID NO: 6 or the complementary thereof, and b) determining therefrom the presence or absence and/or the quantity of HIV-2 nucleic acids in the biological sample.
University of Rouen and Targedys | Date: 2017-08-09
The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of a ClpB protein or an effective amount of a bacterium that expresses the ClpB protein.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-02-2014 | Award Amount: 6.15M | Year: 2015
Prime objective of the Sharc25 project is to develop super-high efficiency Cu(In,Ga)Se2 (CIGS) solar cells for next generation of cost-beneficial solar module technology with the world leading expertise establishing the new benchmarks of global excellence. The project partners ZSW and EMPA hold the current CIGS solar cell efficiency world records of 21.7% on glass and 20.4% on polymer film, achieved by using high (~650C) and low (~450C) temperature CIGS deposition, respectively. Both have developed new processing concepts which open new prospects for further breakthroughs leading to paradigm shift for increased performance of solar cells approaching to the practically achievable theoretical limits. In this way the costs for industrial solar module production < 0.35/Wp and installed systems < 0.60/Wp can be achieved, along with a reduced Capex < 0.75/Wp for factories of >100 MW production capacity, with further scopes for cost reductions through production ramp-up. In this project the performance of single junction CIGS solar cells will be pushed from ~21% towards 25% by a consortium with multidisciplinary expertise. The key limiting factors in state-of-the-art CIGS solar cells are the non-radiative recombination and light absorption losses. Novel concepts will overcome major recombination losses: combinations of increased carrier life time in CIGS with emitter point contacts, engineered grain boundaries for active carrier collection, shift of absorber energy bandgap, and bandgap grading for increased tolerance of potential fluctuations. Innovative approaches will be applied for light management to increase the optical path length in the CIGS absorber and combine novel emitter, front contact, and anti-reflection concepts for higher photon injection into the absorber. Concepts of enhanced cell efficiency will be applied for achieving sub-module efficiencies of >20% and industrial implementation strategies will be proposed for the benefit of European industries.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.93M | Year: 2016
Industries are in need of highly skilled academically trained experts and powerful sets of tools enabling the design, control & prediction of optimized & efficient production process of future high-value products such as chiral pharmaceuticals. The CORE Network will in parallel train 15 ESRs and develop tools, approaches and methods within the area of Continuous Resolution (CORE), the process to obtain enantiopure molecules of chiral compounds. The training objective of the CORE network is to deliver a CORE skills toolbox of knowledge, personal, organizational and impact skills to a core of multi-disciplinary scientists and engineers in the interdisciplinary and cross-sectional field of Continuous Resolution. Each ESR obtains dedicated training through their research project, network events, a webinar course, management involvement and an academic & industrial secondment. The research objective of the CORE Network is to jointly construct a CORE Industrial Toolbox on Continuous Resolution that provides next generation tools, approaches and methods to industry for the development continuous resolution processes. The strongly involved industrial partners will ensure that the CORE Industrial Toolbox fulfils their requirements in the skills gap areas Towards Continuous, Hybrid Resolution and Enabling Resolution. CORE brings together 8 academic and 7 industrial partners resulting in an unparalleled combination of chirality, synthesis and crystallization training and research covering the areas of Chemical Engineering, Chemistry and Applied Physics.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-25-2015 | Award Amount: 4.09M | Year: 2016
According to the World Health Organisation (WHO, ADI), 44 million people around the world have some form of dementia, for which there is no effective intervention, to halt or reverse the progressive cognitive impairment. As Europes population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of care. In this project, we will build a mHealth application that is specifically targeted to caregivers and patients with mild to moderate dementia. The result is CAREGIVERSPRO-MMD: a tool integrating a broader diagnostic approach, incorporating the live-in family caregiver-patient dyad and considering this dyad as the unit of care. CAREGIVERSPRO-MMD will provide value-added services based on social networks, tailored interventions, clinical strategies and gamification for improving quality of life for dementias patients and caregivers that allow them to live in the community for as long as possible. The project will comprise three phases: first, we will develop new services for patients with mild to moderate dementia and their respective caregivers to an existing application. In the second phase, we will conduct a user-centric analysis to re-design the existing application for patients with mild to moderate dementia. The development will be steered by patients, carers and doctors, through user-centric design: we will collect feedback on each new version of the application until the design is adapted to the users needs. In the third phase, we will pilot the optimised application with 550 dyads (patients and their respective caregivers) and 550 controls. This will show the clinical and social benefits for patients and caregivers, as well as financial benefits for the healthcare system.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.73M | Year: 2015
The physical and psychosocial impact of armed conflict on children is immense and particularly so, if these children are associated with the enemy. Overwhelming evidence suggests that children born of war (CBOW), i.e. children fathered by foreign soldiers and born to local mothers have been and continue to be a major obstacle to successful integration of both their mothers and themselves into post-conflict societies. At a global level, previous UN studies have further emphasized the lack of research on children born out of forced pregnancies in armed conflict. The proposed network addresses the described shortcomings by advancing the knowledge base through systematic analysis of lived experiences of CBOW in a variety of 20th century conflict and post-conflict situations. The main research goal is to further our understanding of how (if at all) CBOW in conflict and post-conflict situations are integrated into society; how (if at all) militaries, governments, and nongovernmental policy makers assist this integration process; and how the childrens lived experiences reflect broader societal attitudes to memories of war and vice versa. Our vision is to promote scientific excellence by exploiting the specific research expertise and infrastructure of the co-ordinating partner and all participants in order to advance the research competencies and employability of early career researchers. Their enhanced understanding of the challenges of CBOW in volatile societies will inform the normative debates and, ultimately, policies on the reintegration of CBOW into post-conflict societies. By combining historical, social empirical, psychiatric, political, legal, memory, public health and development studies with the discourse surrounding currently enacted humanitarian intervention, insights gained from this network will surpass existing knowledge and will help improve on current integration efforts.
Coquerel G.,University of Rouen
Chemical Society Reviews | Year: 2014
The aim of the tutorial review is to show that any crystallization from solution is guided by stable or metastable equilibria and thus can be rationalized by using phase diagrams. Crystallization conducted by cooling, by evaporation and by anti-solvent addition is mainly considered. The driving force of crystallization is quantified and the occurrence of transient metastable states is logically explained by looking at the pathways of crystallization and the progressive segregation which might occur in a heterogeneous system. This journal is © the Partner Organisations 2014.